CancerVax, Inc., the developer of a revolutionary universal cancer treatment platform that will use the body’s immune system to treat cancer, announced today that Sumant Ramachandra, MD, PhD, MBA and founder of SR Global Health, LLC, a healthcare advisory firm, will serve as the Company’s new Chief Scientific Advisor
CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the body’s immune system to treat cancer, today announced the successful functional validation of its innovative Smart mRNA (messenger RNA) technology in lab tests
CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the body’s immune system to treat cancer, announced today that the Company has selected Pancreatic Ductal Adenocarcinoma (PDAC) as one of its first targets for preclinical development
CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that will use the body’s immune system to treat cancer, announced today that Dr. George Katibah will serve as the company’s Chief Scientific Officer
